| | Webinar: Digitize Remote Site Monitoring with Box Tuesday, October 13 | 2pm ET / 11am PT Fierce Pharma is teaming up with Box to discuss how your life sciences organization can continue to propel therapies & devices through the value chain with faster and even more secure site monitoring and auditing. Accelerate R&D processes across the value chain, maintain GxP compliance and reduce your overall IT footprint. Save Your Spot! |
Gilead Sciences' remdesivir cuts COVID-19 death risk in patients on low-flow oxygen Eli Lilly's Olumiant pares COVID-19 patients' recovery time down to 7 days as an add-on to remdesivir Preventive care dropped during COVID-19 pandemic despite rise in telehealth visits: study Fauci weighs in on Regeneron's Trump-backed COVID-19 drug: 'Good chance' it helped him CMS alerts providers to changes to Medicare advance loan repayments, giving hospitals more time HCA to return $6B in CARES Act funding, including more than $4B in Medicare accelerated payments Biopharma roundup: FDA tracking 550 COVID drug programs; BARDA adds another CRO to countermeasures network Stopping COVID-19 by targeting out-of-control immune cells AMA announces new CPT codes for tests aimed at detecting COVID-19 and flu KFF: Program to reimburse providers for treating uninsured COVID-19 patients has several limitations BARDA taps Pharm-Olam to join its trial network as it boosts CRO contracts Featured Story | By Eric Sagonowsky Gilead Sciences’ remdesivir has been a crucial treatment for COVID-19 for months, but new data from a “gold standard” trial give a clearer picture of the med’s benefit. The drug improved recovery times, reduced chances of patients progressing to more severe stages of illness and significantly cut the risk of death in a subset of patients. read more |
| |
|---|
|
Top Stories By Kyle Blankenship Months into the COVID-19 pandemic, just two therapies have emerged as FDA-approved emergency therapies hospitalized patients. Last month, Eli Lilly rolled out findings for rheumatoid arthritis med Olumiant in an effort to become the third—and new data shows the extent of the drug's effect on improving recovery. read more By Heather Landi Despite the interest in telehealth fueled by the pandemic, virtual care didn't fill in the gap for missed primary care appointments, according to a study published in JAMA Open. Here is why researchers are concerned about the quality of primary care with the telehealth boom. read more By Ben Adams Infectious disease expert Anthony Fauci, M.D., has said of Regeneron’s experimental antibody cocktail that: “There is a reasonably good chance that in fact it made [President Donald Trump] much better.” read more By Robert King CMS alerted providers to major changes to the Medicare advance loan repayment terms, including how financially strapped hospitals can get more time to repay. read more By Tina Reed HCA Healthcare is returning $6 billion in COVID-19 relief funds it received as part of the Coronavirus Aid, Relief, and Economic Security Act earlier this year. read more By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner The FDA said it is tracking over 550 individual drug programs, outside of vaccines, currently making their way through the planning stages for use against COVID-19. Meanwhile, BARDA tapped the CRO Pharm-Olam to join its clinical studies network for medical countermeasures—its second newcomer this week, after PRA Health. read more By Arlene Weintraub A Johns Hopkins team found that blocking the protein factor D prevented the process by which SARS-CoV-2 over-stimulates the immune response, causing the destruction of healthy cells in the lungs, blood vessels and organs. They believe the discovery could inspire new treatments to prevent severe COVID-19 symptoms. read more By Tina Reed The American Medical Association announced new CPT codes for multi-virus tests used to detect COVID-19 and flu with a single test. read more By Robert King Limitations such as strict coding requirements could be why few providers are getting reimbursements for treating uninsured COVID-19 patients. read more By Ben Adams Pharm-Olam has become the latest contract research organization to be added into BARDA’s Clinical Studies Network. read more | 